IZTC חוב כולל להון Invizyne Corp
The price chart for Invizyne Technologies Inc. (IZTC) demonstrates a total debt-to-equity ratio of 0.00, while the business positions itself as an innovator in the cell-free synthesis of complex compounds. The company is optimizing raw material costs through R&D partnerships with bioengineering startups. The market has currently priced in patent expenses, anticipating a transition from prototypes to the commercial licensing of the platform.
פילוחי מדדים מקיפים ואנליטיקה עבור Invizyne Corp (IZTC)
The ratio is calculated as total liabilities divided by equity, measuring the degree of financial autonomy and the business's leverage level. By analyzing the company's leverage history, an investor assesses the balance between bankruptcy risks and the use of borrowed funds to scale the unique SimpleCell cell-free platform, whose strong pricing power in biopharmaceuticals allows Invizyne Technologies Inc. (IZTC) to efficiently service its debt.